ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.
|Published (Last):||20 September 2004|
|PDF File Size:||17.57 Mb|
|ePub File Size:||19.52 Mb|
|Price:||Free* [*Free Regsitration Required]|
Identify wcog efficacy findings from the four large randomized trials assessing platinum-taxane combinations in advanced NSCLC. Patient and tumor characteristics were similar across treatment groups. Ultimately new drugs against new targets are the future of lung cancer therapy.
Despite the disappointing results of ECOGthere were fcog trials describing new agents with novel mechanisms of action reported at this year’s ASCO meeting. Am J Clin Oncol. To Recreate Risk Factors and Prognosis? Consensus on clinical practice.
While response rate is a useful surrogate marker, survival is ultimately the best indicator of the success or failure of a treatment. Results and conclusions of that meeting are presented in this paper. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Also, with the growing acceptance and momentum favoring treatment of patients with metastatic NSCLC, investigators are placing patients on trial that are more reflective of the general population of lung cancer patients.
Prognostic factors in non-small cell lung cancer: From the Cover Conflict of Interest: Time to progression was chosen as an endpoint because this was a randomized phase II study and patients on the chemo-alone arm were allowed to cross over to anti-VEGF upon progression. Population-based study of 20 cases. Participation of patients 65 years of age or older in cancer clinical trials. However, there is no consistent evidence that combination chemotherapy without platinum is better than third generation drugs given as single agents.
J Clin Oncol ; CrossRef Medline Google Scholar.
Role of new targeted agents. Would prophylactic irradiation to the mediastinum prevent fatal hemoptysis? Patients treated with cisplatin underwent hydration and received antiemetics.
The original sample size was significantly larger, but the trial was stopped early when the interim analysis showed a significant benefit to the experimental arm in terms of improved overall survival. The docetaxel-platinum combination demonstrated broad QOL benefits for patients receiving this combination, and this benefit was not observed with the other platinum or taxane-platinum combinations.
As a result of their single-agent activities and synergistic effects, taxane-platinum combinations are often used as first-line therapy for this disease. Taking into account the superiority shown by the carboplatin—paclitaxel combination compared to paclitaxel alone, even in PS2 patients, in one clinical trial [ 37 ], carboplatin-based doublets may also be considered as an alternative option in a selected sub-group of patients.
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
Activity of docetaxel in platinum-treated non-small-cell lung cancer: Proc Am Soc Clin Oncol. The Japanese study showed an impressive survival advantage to the newer combination.
In a series of more than patients with inoperable lung cancer analysed more than two decades ago to investigate the impact on survival of 50 prognostic factors, performance status, extent of disease and weight loss were among the most important prognostic factors [ 19 ]. A Review James R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer.
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Some of the data considered by the panellists still lack peer-review quality and are possibly not definitive.
The study by Noda et al.